Minerva Neurosciences (NASDAQ:NERV) Now Covered by StockNews.com

Analysts at StockNews.com initiated coverage on shares of Minerva Neurosciences (NASDAQ:NERV) in a research report issued to clients and investors on Thursday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright cut their target price on shares of Minerva Neurosciences from $7.00 to $5.00 and set a “neutral” rating for the company in a research report on Wednesday, August 7th.

Minerva Neurosciences Stock Down 2.7 %

Shares of NERV stock opened at $2.51 on Thursday. The company has a 50 day moving average price of $2.70 and a 200-day moving average price of $2.80. Minerva Neurosciences has a 52 week low of $2.26 and a 52 week high of $13.49. The firm has a market capitalization of $17.55 million, a PE ratio of -0.56 and a beta of 0.14.

Minerva Neurosciences (NASDAQ:NERV) last released its quarterly earnings results on Tuesday, August 6th. The biopharmaceutical company reported ($1.09) earnings per share for the quarter, missing the consensus estimate of ($0.97) by ($0.12). Analysts anticipate that Minerva Neurosciences will post -2.26 earnings per share for the current year.

About Minerva Neurosciences

Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders.